PPARG and chronic obstructive pulmonary disease: Clinical evidence suggests that PPARγ and PPARγ ligands are involved in regulating inflammatory responses in the lung [36, 37], and chronic or dysregulated inflammation is an important pathologic feature in many lung diseases including asthma, COPD, sarcoidosis, and pulmonary fibrosis.